Vigilare Wealth Management Purchases 450 Shares of Eli Lilly and Company $LLY

Vigilare Wealth Management increased its position in shares of Eli Lilly and Company (NYSE:LLY) by 32.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,819 shares of the company’s stock after acquiring an additional 450 shares during the period. Vigilare Wealth Management’s holdings in Eli Lilly and Company were worth $2,106,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in LLY. BlackRock Inc. boosted its holdings in shares of Eli Lilly and Company by 1.6% in the 2nd quarter. BlackRock Inc. now owns 67,540,400 shares of the company’s stock valued at $81,009,981,000 after purchasing an additional 1,046,558 shares in the last quarter. State Street Corp increased its stake in shares of Eli Lilly and Company by 1.7% in the 2nd quarter. State Street Corp now owns 36,215,754 shares of the company’s stock valued at $43,438,262,000 after purchasing an additional 605,752 shares during the last quarter. Bank of America Corp DE bought a new position in shares of Eli Lilly and Company in the 2nd quarter valued at $13,522,666,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Eli Lilly and Company by 1.9% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,209,385 shares of the company’s stock worth $8,647,153,000 after buying an additional 137,364 shares in the last quarter. Finally, Jennison Associates LLC raised its holdings in shares of Eli Lilly and Company by 7.9% during the 2nd quarter. Jennison Associates LLC now owns 5,461,416 shares of the company’s stock worth $6,550,587,000 after buying an additional 400,538 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Stock Down 0.4%

Shares of NYSE:LLY opened at $1,412.06 on Tuesday. Eli Lilly and Company has a 52-week low of $850.51 and a 52-week high of $1,449.68. The company has a market capitalization of $1.33 trillion, a PE ratio of 45.83, a price-to-earnings-growth ratio of 1.73 and a beta of 0.46. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.00 and a current ratio of 1.35. The company has a fifty day moving average of $1,200.81 and a 200-day moving average of $1,094.25.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, October 29th. The company reported $7.48 earnings per share for the quarter, beating the consensus estimate of $5.71 by $1.77. The company had revenue of $24.40 billion for the quarter, compared to the consensus estimate of $22.58 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%. Eli Lilly and Company’s revenue for the quarter was up 38.6% on a year-over-year basis. During the same quarter last year, the business posted $7.02 EPS. On average, equities analysts predict that Eli Lilly and Company will post 35.18 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be paid a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date of this dividend is Friday, November 13th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 22.46%.

Insider Activity

In other news, EVP Anat Hakim sold 5,000 shares of the business’s stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the sale, the executive vice president directly owned 11,875 shares in the company, valued at approximately $14,131,250. The trade was a 29.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the company’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the completion of the transaction, the executive vice president directly owned 54,147 shares of the company’s stock, valued at $63,628,139.70. This represents a 10.72% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 13,500 shares of company stock valued at $15,958,170. 0.14% of the stock is currently owned by corporate insiders.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Another strong quarter and higher guidance: Third-quarter revenue rose roughly 39% year over year to $24.4 billion, beating expectations, while adjusted EPS also exceeded estimates. Strong demand for Mounjaro and Zepbound led Lilly to raise its full-year outlook. Eli Lilly Just Delivered Another Blowout Quarter
• Positive Sentiment: Analyst price-target increases: Cantor Fitzgerald raised its target to $1,600 and maintained an “overweight” rating. Other firms, including JPMorgan, also boosted targets, reflecting continued confidence in Lilly’s earnings outlook. Cantor Fitzgerald price target
• Neutral Sentiment: Commercial reorganization: Lilly is combining its U.S. and international commercial operations into one division. The move could improve coordination and execution globally, but its financial effect is not yet clear. Lilly combines commercial divisions
• Negative Sentiment: Pricing and growth concerns: Medicare’s GLP-1 Bridge program and lower realized drug prices may pressure revenue and margins. Analysts also warn that growth could moderate after exceptionally strong results, while one-time revenue benefits may not recur. Lilly’s First Full Medicare Quarter
• Negative Sentiment: High expectations and concentration risk: With about two-thirds of revenue tied to its leading GLP-1 medicines and the shares trading at a premium valuation, investors may be taking profits and demanding evidence that rapid growth can continue. Eli Lilly: Softer Growth Ahead

Wall Street Analysts Forecast Growth

LLY has been the subject of several recent analyst reports. HSBC upped their price objective on Eli Lilly and Company from $850.00 to $940.00 and gave the stock a “reduce” rating in a research report on Thursday, September 10th. Cantor Fitzgerald boosted their target price on Eli Lilly and Company from $1,440.00 to $1,600.00 and gave the stock an “overweight” rating in a research note on Monday. Scotiabank increased their target price on shares of Eli Lilly and Company from $1,300.00 to $1,605.00 and gave the stock a “sector outperform” rating in a report on Friday. Citigroup raised their price target on shares of Eli Lilly and Company from $1,600.00 to $1,650.00 and gave the company a “buy” rating in a research note on Friday. Finally, TD Cowen restated a “buy” rating and issued a $1,250.00 price target on shares of Eli Lilly and Company in a research note on Tuesday, September 22nd. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Eli Lilly and Company has a consensus rating of “Moderate Buy” and an average target price of $1,404.14.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.